Nineteen major depressed patients, resistant to previous pharmacotherapies, were treated by the addition of moclobemide (up to 600 mg/day) to paroxetine or fluoxetine (20 mg/day) for 6 weeks in an open study to assess the adverse events and tolerability. There were 77 emergent events, insomnia, headache, nausea and dizziness being the most common. Many events were rated as severe. The high rate of adverse events suggests that there may be clinically significant interactions between moclobemide and SSRIs. However, the uncontrolled data on effectiveness is encouraging and the combination deserves further attention as a strategy for treating intractable major depression.
Austin Mpv, Souza F G M, Goodwin GM (1991) Lithium augmentation in antidepressant resistant patients. A quantitative analysis. Br J Psychiatr159: 510-514
2.
Bakish D., West D.L., Miller C., Bashir F., Hooper C. (1994) Moclobemide and specific serotonin re-uptake inhibitor combination treatment. Neuropsychopharmacology10(2): 199-292
3.
Boyer W.F., Feigher J.P. (1991) Selective serotonin re-uptake inhibitors. John Wiley & Sons Ltd
4.
Chaimowitz G.A., Links P.S., Padgett R.W., Carr A.C. (1991) Treatment resistant depression: a survey of practice habits of Canadian psychiatrists. Can J Psychiatr36(5): 353-356
5.
Dingemanse J. (1993) An update of recent moclobemide interaction data . Int Clin Psychopharmacol7:167-180
6.
Dingemanse J., Eckernas SA, Grahnen A., Hass G., Wallnofer A. (1991) Tolerability and safety of combined fluvoxamine and moclobemide in healthy volunteers. Eur Neuropsychopharmacol1(3): 86
7.
Elkin I., Shea T., Watkins J.T. et al. (1989) National Institute of Mental Health Treatment of Depression Collaborative Research Program: general effectiveness of treatments . Arch Gen Psychiatr46: 971-982
8.
Guy W. ( 1976) ECDEU assessment manual for psychopharmacology, US Department of Health Education and Welfare publication ADM 76-338. National Institute of Mental Health, Rockville, MD , pp. 217-222
9.
Hawley CJ, Roberts AG, Walker MH (1994a) Tolerability of combined treatment with lithium and paroxetine: 19 cases treated under open conditions. J Psychopharmacol8: 266-267
10.
Hawley CJ, Roberts AG, Baldwin D.S. (1994) Tolerability of combined treatment with lithium and fluoxetine: 14 cases treated under open conditions. Int Clin Psychopharmacol9:31-33
11.
Hawley C.J., Pattinson H A., Quick S J., Echlin D., Smith V. (In press) A protocol for the pharmacologic treatment of major depression— a field test of a potential prototype
12.
Jenner P.N. (1992) Paroxetine: an overview of dosage, tolerability and safetyInt Clin Psychopharmacol6 (Suppl 4): 69-80
13.
Joffe RT, Bakish D. (1994) Combined SSRI-moclobemide treatment of psychiatric illness. J Clin Psychiatr55: 24-25
14.
Joffe RT, Singer W., Levitt AJ, MacDonald C. (1993) A placebo controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressant in unipolar refractory depression. Arch Gen Psychiatr50:387-393
15.
Katona C.L. (1991) Refractory depression. In Freeman H I (ed.), The uses of fluoxetine in clinical practice . Royal Society of Medicine Services International Congress and Symposium Series, No. 183. Royal Society of Medicine Services Limited
16.
Katona C.L., Abou-Saleh M., Harrison D.A., Nairac BA, Edwards D.R., Lock T., Burns R.A., Robertson M.M. (1995) Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatr166: 80-86
17.
Keller M.B. (1994) Depression: a long term illness. Br J Psychiatr165 (Suppl 26): 9-15
18.
Marley E., Wozniak K.M. (1984a) Interactions of a non-selective monoamine oxidase inhibitor, phenelzine, with inhibitors of 5-hydroxytryptamine, dopamine and noradrenaline re-uptake. J Psychiatr Res18: 173-189
19.
Marley E., Wozniak KM (1984b) Interactions of non-selective monoamine oxidase inhibitors, tranylcypromine and nialamide, with inhibitors of 5-hydroxytryptamine, dopamine and noradrenaline re-uptake. J Psychiatr Res18:191-203
20.
Nelson J.C. (1993) Combined treatment strategies in Psychiatry. J Clin Psychiatr54 (Suppl): 42-49
21.
Neuvonen PJ, Pohjola S.S., Tacke U., Vuori E. (1993) Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet342:1419
22.
Radomski J.W., Dursun S.M., Reveley M.A. (1995) Toxic serotonin syndrome (TSS): an update and revised diagnostic criteria. J Psychopharmacol1(3) (Suppl): A21 (84)
23.
Stein G., Bernadt M. (1993) Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses. Br J Psychiatr162: 634-640
24.
Sternbach H. (1991) The serotonin syndrome. Am J Psychiatr148: 705-713
25.
Williams R., Edwards R.A., Newburn G.M., Mullen R., Menkes, Segkar C. (1993) A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders. Int Clin Psychopharmacol7:155-158
